C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) CCCC, a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will present at the 40^th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 10:30 a.m. EST.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.c4therapeutics.com. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.

About C4 Therapeutics

C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.c4therapeutics.com.

Investor Contact: 

Kendra Adams 

SVP, Communications & Investor Relations 

Kendra.Adams@c4therapeutics.com

Media Contact: 

Loraine Spreen 

Director, Corporate Communications & Patient Advocacy 

LSpreen@c4therapeutics.com